Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin recepto…
Biotechnology
US, Seattle [HQ]
Ratios
8 Sheets · From 2022 to 2015Configuration
Margins, Growth Rates In %
| Ratio | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|---|---|---|---|
| Profitability | |||||||||
| Gross Margin | 99.88 | 98.92 | 96.76 | 96.13 | 96.79 | 48.97 | 96.73 | 71.90 | |
| Profit Margin | -53.73 | -179.85 | -532.88 | -632.05 | -271.47 | -9,869.65 | -196.22 | -3,012.65 | |
| Operating Margin | -18.59 | -141.79 | -617.51 | -671.84 | -115.69 | -6,798.91 | -191.84 | -3,020.28 | |
|
EPS Growth
|
- - | -55.56 | 7.14 | 7.69 | -92,400.00 | -458.56 | 64.19 | -29.28 | |
| EPS USD | -0.09 | -0.14 | -0.13 | -0.12 | -111.00 | -620.00 | -222.00 | -287.00 | |
| Return on Assets (ROA) | -8.14 | -20.78 | -20.64 | -26.67 | -298.00 | -19.03 | -17.97 | -32.16 | |
| Return on Equity (ROE) | -14.99 | -40.11 | -38.68 | -70.47 | 113.94 | -24.39 | -22.33 | -41.77 | |
| Return on Invested Capital (ROIC) | -5.17 | -21.89 | -49.76 | -75.52 | 54.42 | -13.13 | -18.67 | -36.39 | |
| Solvency | |||||||||
| Equity Ratio | - - | - - | - - | - - | -200 | - - | - - | - - | |
| Debt/Assets | - - | - - | - - | - - | 13.26 | 9.73 | 7.80 | 6.87 | |
| Debt/Equity | - - | - - | - - | - - | -5.07 | 12.48 | 9.70 | 8.93 | |
| Debt/EBITDA | 1,109.23 | 104.27 | 148.06 | 124.62 | 46.89 | 270.45 | 240.92 | 46.28 | |
|
Debt/Capitalization
|
- - | - - | - - | - - | -5.34 | 11.09 | 8.84 | 8.19 | |
| Long-Term Debt/Capitalization | - - | - - | - - | - - | -4.70 | 10.37 | 8.03 | 7.24 | |
| Interest Debt per Share USD | - - | - - | - - | - - | 0.05 | 3.17 | 0.96 | 0.72 | |
| Debt Growth | - - | - - | - - | - - | - - | 1,903.55 | 5.36 | -10.34 | |
| Liquidity | |||||||||
| Current Ratio | 1,366.46 | 1,158.15 | 845.71 | 927.27 | 516.32 | 1,113.95 | 750.00 | 758.52 | |
| Quick Ratio | 1,353.57 | 1,137.93 | 790.06 | 912.53 | 6,820.07 | 1,085.69 | 740.67 | 746.37 | |
| Cash Ratio | 484.31 | 244.62 | 380.70 | 413.90 | 461.60 | 823.14 | 453.35 | 227.08 | |
| Operating Cash Flow Ratio | 400 | -200 | -200 | -200 | -500 | -200 | -200 | -200 | |
| Turnover | |||||||||
| Inventory Turnover | - - | - - | - - | - - | -18.64 | - - | - - | - - | |
| Receivables Turnover | 1,505.96 | 4,453.52 | 1,743.07 | 125.34 | 5,046.20 | 315.65 | 513.12 | 561.69 | |
| Payables Turnover | 1.75 | 24.89 | 48.61 | 40.08 | 59.00 | 10.56 | 19.66 | 17.66 | |
|
Asset Turnover
|
15.15 | 11.55 | 3.87 | 4.22 | 109.77 | 0.19 | 9.16 | 1.07 | |
| Fixed Turnover | 1,830.88 | 192.09 | 55.46 | 51.74 | 540.83 | 1.08 | 69.46 | 9.30 | |
| Coverage | |||||||||
| Interest Coverage | -2,745.75 | -3,238.53 | - - | - - | -60,503.03 | -374,846.67 | - - | -2,578.48 | |
| Asset Coverage | - - | - - | - - | - - | -200 | 800 | 1,000 | 1,100 | |
| Cash Flow Coverage (CFGR) | - - | - - | - - | - - | -652.02 | -133.75 | -233.56 | -297.86 | |
| EBITDA Coverage | -2,700 | -3,200 | - - | - - | -58,900 | -359,800 | - - | -2,200 | |
| Dividend Coverage | - - | - - | - - | - - | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | - - | - - | - - | - - | - - | - - | - - | - - | |
| Market Prospects | |||||||||
| Dividend Yield | - - | - - | - - | - - | - - | - - | - - | - - | |
| Earnings Yield | - - | - - | - - | -0.01 | -18.84 | -39.08 | -13.62 | -10.95 | |
|
Price/Earnings (P/E)
|
-16,042,718.50 | -4,077,372.44 | -2,975,948.49 | -1,090,977.88 | -530.91 | -255.87 | -734.30 | -913.52 | |
| Price/Earnings Growth (PEG) | - - | -73,392.70 | 416,632.79 | 141,827.12 | -0.01 | -0.56 | 11.44 | -31.20 | |
|
Price/Book (P/B)
|
2,404,304.49 | 1,635,614.57 | 1,151,202.69 | 768,839.02 | -604.91 | 62.41 | 163.97 | 381.61 | |
| Price/Tangible Book (P/TB) | 2,404,304.49 | 1,635,614.57 | 1,151,202.69 | 768,839.02 | -604.91 | 62.41 | 163.97 | 381.61 | |
| Price/Sales (P/S) | 8,619,177.43 | 7,333,011.25 | 15,858,202.69 | 6,895,497.93 | 1,441.27 | 25,253.26 | 1,440.87 | 27,521.12 | |
|
Price/Cash Flow (P/CF)
|
4,063,167.43 | -4,317,630.27 | -3,076,658.37 | -1,513,000.15 | -1,830.55 | -373.95 | -723.98 | -1,435.55 | |
| Price/Free CF (P/FCF) | 4,121,039.27 | -3,379,721.76 | -2,907,983.79 | -1,462,690.19 | -1,733.83 | -368.69 | -710.99 | -1,415.63 | |
| Price/Operating CF (P/OCF) | 4,063,167.43 | -4,317,630.27 | -3,076,658.37 | -1,513,000.15 | -1,830.55 | -373.95 | -723.98 | -1,435.55 |